6:09 PM
 | 
Nov 12, 2012
 |  BC Extra  |  Financial News

Celgene, Abraxis CVR soar on Abraxane data

Celgene Corp. (NASDAQ:CELG) gained $4.16 to $75.66 on Monday after reporting late Friday that Abraxane nab-paclitaxel met the primary endpoint of overall survival (OS) vs. gemcitabine alone in the Phase III MPACT trial to treat metastatic pancreatic cancer in treatment-naïve...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >